{
  "source": "PA-Notification-Egrifta.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1027-13\nProgram Prior Authorization/Notification\nMedication Egrifta SV™ (tesamorelin for injection)\nP&T Approval Date 5/2011, 5/2012, 5/2013, 4/2014, 4/2015, 2/2016, 2/2017, 2/2018, 2/2019,\n2/2020, 2/2021, 2/2022, 2/2023, 2/2024, 2/2025\nEffective Date 5/1/2025\n1. Background:\nEgrifta SV (tesamorelin) is a growth hormone releasing factor (GHRF) analog indicated for the\nreduction of excess abdominal fat in HIV-infected patients with lipodystrophy.\nLimitations of Use:\n• Long-term cardiovascular safety of Egrifta SV has not been established.\n• Not indicated for weight loss management.\n• There are no data to support improved compliance with anti-retroviral therapies in HIV-positive\npatients taking Egrifta.\nCoverage for Egrifta will be provided for patients who meet the following criteria:\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Egrifta will be approved based on the following criterion:\na. Diagnosis of HIV-associated lipodystrophy\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Egrifta will be approved based on the following criterion:\na. Documentation of positive clinical response (e.g., improvement in visceral adipose\ntissue [VAT], decrease in waist circumference, belly appearance) while on Egrifta\ntherapy.\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n© 2025 UnitedHealthcare Services, Inc.\n1\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Egrifta [presc",
    "sis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Egrifta [prescribing information]. Montreal, Quebec, Canada: Theratechnologies, Inc.; February\n2024.\nProgram Prior Authorization/Notification – Egrifta (tesamorelin for injection)\nChange Control\n4/2014 Annual review with age assessment resulting in no change in clinical\ncoverage. Updated references.\n4/2015 Annual review with no change in clinical coverage. Updated references.\n2/2016 Annual review. Modified initial coverage criteria to require only a\ndiagnosis. Updated references.\n2/2017 Annual review. No change in clinical coverage.\n2/2018 Annual review. No change in clinical coverage.\n2/2019 Annual review. No change in clinical coverage.\n2/2020 Annual review. Updated reauthorization duration to 12 months.\n2/2021 Annual review. No changes to clinical coverage. Updated background and\nreferences.\n2/2022 Annual review. No changes to clinical coverage.\n2/2023 Annual review with no changes to coverage criteria. Updated background,\nreferences and added state mandate footnote.\n2/2024 Annual review with no changes to coverage criteria.\n2/2025 Annual review. Updated initial authorization to 12 months and updated\nreference.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}